New Product Sales Drive Gilead Sciences Sales Higher By 21%

The good times continued for biopharma giant Gilead Sciences (NASDAQ: GILD  ) after the closing bell on Tuesday, as the company reported double-digit sales and EPS growth for the fourth quarter.

For the quarter, Gilead delivered a total revenue increase of 21% to $3.04 billion as adjusted profits improved 10% to $0.55 from $0.50 in the year-ago period.

The majority of Gilead's growth came from its antiviral product line which saw sales rise 22% to $2.64 billion, yet growth was dominated by its newer drugs. Sovaldi, the company's oral hepatitis-C pill approved in December, had revenue of $139.4 million during the quarter, driven by clinical trial sales, as well as patient demand and inventory stocking. Similarly, Stribild, the company's four-in-one HIV medication, saw sales more than quintuple to $203.8 million from $40 million in the year-ago period. Finally, HIV drug Complera/Eviplera saw sales increase 122% to $261.8 million.

Gilead's leading drugs, based on sales, were Atripla and Truvada, which brought in $933.6 million and $814.1 million, respectively. Revenue for these two drugs gained 2% and fell 2%, respectively, but their weakness shouldn't come as a surprise to shareholders since Stribild is built to become the next-generation HIV therapy.

Gilead's cardiovascular segment, while small, also delivered strong sales gains of 25% to $268.5 million with Letairis sales up 19% and Ranexa revenue up 31%.

Looking ahead, Gilead anticipates full-year 2014 revenue of $11.3 billion to $11.5 billion, with gross product margin of 75%-77% and EPS ranging from $0.63-$0.66. One factor to consider, though, is that these figures exclude the impact of Sovaldi on revenue and EPS projections.


Read/Post Comments (0) | Recommend This Article (7)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2823571, ~/Articles/ArticleHandler.aspx, 9/2/2014 3:26:28 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement